Key result
Candesartan reduces urinary endogenous Ang II excretion by ~66% in Ang II-infused rats.
Why the study?
Does AT1 receptor blockade with candesartan prevent the augmentation of intrarenal and urinary excretion of endogenous Ile5-Angiotensin II in rats chronically infused with Val5-Angiotensin II?
Does AT1 receptor blockade with candesartan prevent the augmentation of intrarenal and urinary excretion of endogenous Ile5-Angiotensin II in rats chronically infused with Val5-Angiotensin II?
Demonstrates that increased urinary excretion of endogenous Ang II during chronic Ang II-induced hypertension reflects AT1 receptor-dependent intrarenal de novo formation and/or tubular secretion rather than glomerular filtration of circulating peptide, supporting urinary Ang II as a potential biomarker of intrarenal RAS activity.
Answers are grounded in this paper and cite their sources.
AT1 blockade attenuates intrarenal endogenous Ang II in this rat model; leaves open urinary Ang II as intrarenal RAS biomarker pending human studies.
Rats infused chronically with Val(5)-Angiotensin (Ang) II exhibit increased urinary excretion of endogenous Ile(5)-Ang II by the 12th day of infusion, suggesting the stimulation of endogenous Ang II formation by Val(5)-Ang II infusion. The present study determined the time course of increased urinary Ang II excretion and the effects of Ang II type 1 receptor blockade (candesartan, 2 mg/kg per day) on the urinary excretion rates of Ile(5)-Ang II in Val(5)-Ang II-infused (80 ng/min) rats. Ile(5)-Ang II was separated from Val(5)-Ang II by high-performance liquid chromatography and measured by radioimmunoassay. Systolic blood pressure increased progressively (215+/-2 mm Hg) in Val(5)-Ang II-infused rats (n=5), whereas the candesartan-treated group (n=6) remained normotensive (124+/-3 mm Hg). Candesartan treatment significantly increased the level of plasma Ile(5)-Ang II (24.0+/-7.6 versus 156.9+/-24.6 fmol/mL; P<0.01); in contrast, there was a markedly lower intrarenal Ile(5)-Ang II content (357.9+/-76.6 versus 21.1+/-2.8 fmol/g; P<0.01). Urinary Ile(5)-Ang II excretion rates were elevated by day 9 (2185.7+/-283.2 fmol/24 hours) in Val(5)-Ang II-infused rats but not in candesartan-treated rats (740.6+/-110.3 fmol/24 hours). Thus, Ang II type 1 receptor blockade prevents the increase in urinary excretion of endogenous Ang II in rats subjected to chronic Ang II infusion. These data indicate that the increased urinary excretion of endogenous Ang II in Val(5)-Ang II-infused rats is primarily attributed to Ang II type 1 receptor-dependent secretion into and/or de novo formation of Ang II within the tubular lumen.
No takes yet. Share an insight, caveat, or question.
Shao et al. (2010) studied Angiotensin II-induced hypertension (n=11). Candesartan vs. Val5-Angiotensin II infusion (80 ng/min) alone without candesartan was evaluated on Urinary endogenous Ile5-Angiotensin II excretion rate at day 9 (fmol/24 hours) (p=<0.05). Candesartan prevented the increase in urinary endogenous Ile5-Ang II excretion at day 9 and reduced intrarenal Ile5-Ang II by 94% in Val5-Ang II-infused rats.
Synapse has enriched 10 related papers. Consider them for comparative context: